


PRT62607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers

Coffey et al

Supplemental Figure S2

A Mean Plasma Concentration-Time Profiles for PRT062607 on Day 1 (MAD)



B

Mean (SD) Plasma PK Parameters for PRT062607 on Day 1 (MAD)

PK Parameter	Units	Dose of PRT062607							
		11 mg	N	33 mg	N	66 mg	N	110 mg	N
C_{max}	(ng/mL)	16.1 (9.81)	6	61.4 (36.6)	6	119 (80.8)	6	223 (109)	6
T_{max}^a	(hr)	1.00 (0.500, 1.00)	6	2.00 (0.533, 4.00)	6	2.53 (2.00, 4.00)	6	3.03 (2.00, 6.00)	6
AUC_{0-24}	(ng*hr/mL)	106 (46.7)	6	624 (369)	6	1327 (824)	6	2341 (1143)	6

^a Median (Min, Max) presented for T_{max} .

N = number of subjects studied; SD = standard deviation

Supplemental Figure S2: PK parameters following the first oral administration of PRT062607 in the MAD study. Plasma concentrations (y-axis, in ng/ml) over time (x-axis, in hours) following the first oral dose from the MAD study (A). Dose groups are represented by symbols, as shown. The summary table (B) depicts mean (SD) PK parameters for each dose level on day 1.